摘要
本课题针对RNA编辑酶在结直肠癌大体标本及其癌细胞株HCT-8细胞中的表达,及苯乙酸对结直肠癌HCT-8细胞的增殖抑制作用和RNA编辑酶在结直肠癌细胞诱导分化中的作用进行了实验研究。本实验在细胞水平、亚细胞水平、分子水平分别进行了细胞增殖抑制率检测、流式细胞仪检测、电镜观察及逆转录PCR检测。
本研究检测了RNA编辑酶ADAR1、ADAR2在结直肠癌临床组织标本及癌旁组织中的表达,表明RNA编辑酶ADAR1在结直肠癌组织及癌旁组织中未见明显表达,RNA编辑酶ADAR2在结直肠癌组织中阳性表达、在癌旁组织无表达或弱表达。
本实验通过MTT比色法检测苯乙酸对结直肠癌HCT-8细胞的增殖抑制作用具有时间和剂量依赖性;通过流式细胞仪检测发现苯乙酸使结直肠癌HCT-8细胞阻滞于G0/G1期,使G0/G1期细胞比例下降,S期细胞比例显著增高,且这种作用在撤药后仍可维持;在相差显微镜下观察到经苯乙酸作用后结直肠癌HCT-8细胞形态由不规则多边形向规则圆形转变;电镜下观察到细胞超微结构向正常细胞转化。
本实验还证实RNA编辑酶ADAR2在结直肠癌及癌细胞株中阳性表达,且其表达随苯乙酸对结直肠癌细胞株诱导分化作用的增强而减弱,进而推测其表达与结直肠癌的发生发展有关,其表达变化与苯乙酸对结直肠癌的诱导分化作用机制有关。
Colorectal carcinoma is one of the most common malignant tumors among human beings.In the world,it is the fourth in the common malignant tumors. It is the second main reason of cancer causing death in western countries. The annually morbidity is about 1,023,000 cases , 529,000 men died with colorectal carcinoma annually. The tendency of morbidity is increasing, among the humen beings that over 40 years old ,the morbidity is obviously increasing , adds one times annually, it displays a persistent exponential growth.
It is a result of multi-procedure、polygene heterogeny or activated from the normal colorectal enterocyte to colorectal cancer cells,the pathogenetic related gene of colorectal cancer transformed in different component element in the course of carcinogensis,it included that the activation of oncogene、inactivation of anti-oncogene、the germ line mutateon and methylation of mismatch repair gene.
With the development of molecular biology and genetic technique, gene treatment had gained some results,but it is not satisfactory in the total consequence. The human being gradually realized that it cann’t completely suppressed the growth of cancer with tradition technique.at present,it is not possible that the gene treatment was clinically applicated in wide-bound.
It demonstrated that:malignant tumor is the result of cell proliferation and disdifferentiation,although it is tumor,but it has a ability that it controls normal growth and differentiation.Therefore,with the certain factor influence,tumor cells may change,and alter toward normal cells,which is induced-differentiation to tumor cells,and it has been the new hot field of colorectal carcinoma research.
RNA editing is a biotic basic-phenomenon,and a physiological course which retains normal metabolic activity.It is one of important mechanism which creates biomolecule versatility and complexity.The development of some disease concerned with RNA editing dysfunction. The relation of RNA editing dysfunction and tumor were more and more payed close attention by researchers.At present,it has been indicated that RNA editing enzymes may educe important effect.
Purpose: To investigate the expression of RNA editing in colorectal carcinoma tissue and cells ,and significance in proliferation and differentiation, discuss the effect and mechanism of phenylacetate induced differentiation.
Methods: Use MTT colorimetry to investigate the inhibitory action of phenylacetate to the proliferation of colorectal carcinoma cell HCT-8. Changes of HCT-8 cell cycle phases with different concentration and action time of phenylacetate were detected quantificationaly by floating cytometry. The morphological changes of HCT-8 were detected by phase contrast microscope. The expression of ADAR mRNA in HCT-8 and colorectal carcinoma specimen with and without phenylacetate were detected by RT-PCR.
Results: (1)、Use MTT colorimetry to investigate the inhibitory action of phenylacetate to the proliferation of colorectal carcinoma cell HCT-8. The proliferation inhibitory rate were that:24 hours:4.61%、11.72%、41.09%、65.82%、88.40%; 48 hours:7.55%、27.00%、58.36%、77.02%、88.68%; 72 hours:22.65%、41.36%、89.07%、93.32%、94.45%.The results indicated that the inhibitory action depended on both action time and dosage. (2)、Use floating cytometry to detect changes of HCT-8 cell cycle phases with different concentration and action time of phenylacetate such as 24h and 72h. The results indicated that after using of phenylacetate, the proliferation of HCT-8 cells were inhibited in phase G0/G1, abundant cells accumulated in the end stage of phase S, DNA synthesis could not be accomplished entirely. (3)、The morphological changes of colorectal carcinoma cell HCT-8 without and with different concentration of phenylacetate for 24h、72h were detected by phase contrast microscope. The results indicated that phenylacetate restrained the proliferation of HCT-8, elevated the differentiation stage,and made tumor cells transform to normal cells. (4)、The expression of RNA editing enzymes mRNA in HCT-8 cells、human colorectal carcinoma specimen and tissue beyond carcinoma were detected by RT-PCR.The results indicated that ADAR1 had not visible expression, however ADAR2 had a positive expression in HCT-8 cells、human colorectal carcinoma specimen and tissue beyond carcinoma. (5)、The expression changes of ADAR2mRNA in HCT-8 cells after use of phenylacetate with different concentration and action times were detected by RT-PCR. The gray scale rate of without and with PA in 1.0mM24h,1.0mM72h, 2.0mM24h,2.0mM72h were 1.668±0.060, 1.141±0.030,1.058±0.036, 1.075±0.034,0.894±0.026. The results indicated that the expression of ADAR2 gradually weakened with the increasing of phenylacetate on concentration and action times.
Conclusions: (1)、The inhibitory action of phenylacetate to the cell HCT-8 depended on both action time and dosage. (2)、Through the detection of cell cycle, it indicated that the regulation of cell proliferation and differentiation of HCT-8 may through the effect on HCT-8 cells RNA functional expression, rather than in-specific inhibition to RNA expression. The action point may be phase G1. (3)、High-expression of ADAR2mRNA may related to the occurrence and evolution of colorectal carcinoma. (4)、ADAR2 mRNA played a vital role of regulation in the process of colorectal carcinoma cells growth and differentiation. Phenylacetate could regulate the proliferation and differentiation of colorectal carcinoma cells through the regulation of ADAR2mRNA expression.
引文
1.Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2.Jemal A,Tiwari RC,Mrrray T,et al. American Cancer Society:Cancer statistics. [J] Cancer J Clin,2004,54(1):8-29.
3.Jemal A, Murray T, Ward E, et al. Cancer statistics. Cancer J Clin, 2005, 55(1): 10-30.
4.Wang YG, Chen KX, Wu GL, et al. An analysis: colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol, 2005, 11(6): 895-898.
5. 曹 磊 . 结 肠 直 肠 癌 的 临 床 研 究 进 展 [ J ]. 临 床 肿 瘤 学 杂志,2005,10(2):214-216.
6.董新舒,李志高,徐海涛.直肠癌综合治疗的现状及进展[J].大肠肛门病外科杂志,2004,10(4):235-236.
7.董志伟,乔友林,李连弟,等.中国癌症控制策略研究报告[J].中国肿瘤,2002,11(5):250-260.
8.Cho KR,Vogelstein B.Genetic alterations in the adenoma carcinoma sequence Cancer,1992,15:70(6 suppl):1727-1731.
9. Arango D, Mariadason JM, Wilson AJ, et al. C-myc overexpression sensitizes colon cancer cells to camptothecin-induced apotosis. Br J Cancer, 2003, 89(9): 1757-1765.
10.Tsunoda A, Iijima T, Tsunoda Y, et al. Association of K-ras mutations with liver metastases from colorectal carcinoma. Anticancer Res, 2004, 24(4): 2471-2476.
11. Scopa CD, Tsamandas AC, Zolota V, et al. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. Dig Dis Sci, 2003, 48(10): 1990-1997.
12. Collard TJ, Guy M, Butt AJ, et al. Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis, 2003, 24(3): 393- 401.
13. Seidler HB, Utsuyama M, Nagaoka S, et al. Expression level of Wnt signaling components possibly influences the biological behavior of colorectal cancer in different age groups. Exp Mol Pathol, 2004, 76(3): 224-233.
14. Krishnan K, Aoki T, Ruffin MT, et al. Effects of low dose aspirin on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. Cancer Detect Prev, 2004, 28(2): 107-113.
15. Cianciulli A, Cosimelli M, Marzano R,et al. Genetic and pathologic significance of 1p, 17p, and 18q aneusomy and the ERBB2 gene in colorectal cancer and related normal colonic mucosa. Cancer Genet Cyto genet, 2004, 151(1): 52-59.
16. Heinen CD, Goss KH, Cornelius JR, et al. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology, 2002, 123(3): 751-763.
17.Compton CC. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol, 2003, 16(4): 376-388.
18. Masciullo V,Scambia G,Marone M,et al. Altered expression of cyclinD1 and CDK4 genes in ovarian carcinomas. [J] Int J Cancer,1997,22,74(4):390-395
19.Rivat C, Rodrigues S, Bruyneel E, et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res, 2005, 65(1): 195-202.
20.Lemoine NR,Jain S,Hughes CM et al.K-ras oncogene activation in pre-invasive pancreatic cancer.Gastroenterology,1992;102:230-36.
21.ergham ST,Dugan MC,Kucway R et al.Prevalence and clinical significance of combined K-ras mutation and p53 abberation in pancreatic adenocarcinoma.Int J Pancreatol 1997;21(2):127-43.
22. Vennstrom B,Sheiness D,Zabielski J,et al. Isolation and characterization of c-myc,a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. [J] J Virol,1982,42(3):773-779.
23. Facchini LM,Penn LZ. The molecular role of Myc in growth and transformation:recent discoveries lead to new insights. [J] FASEB J,1998,12(9):633-651.
24. Marcu KB,Bossone SA,Patel AJ. myc function and regulation. [J] Annu J Rev Biochem,1992,61(2):809-860.
25.Smith DR,Myint T,Goh HS.Over-expression of the c-myc proto-oncogene in colorectal carcinoma.Br J Cancer,1993,68:407-413.
26. Sachs L,Lotem J.Control of programmed cell death in normal and leukemic cells:new implication for therapy.Blood,1993,8:15-21.
27. ColombelM,Symmans F,Gil Setal.Detection of the apoptosis suppressing on coprotein bcl 2 in hormone refractory human prostatecancer.AJJ Pathol,1993,143:390-400.
28. Tachibana M, Kawamata H, Fujimori T, et al. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol, 2004, 25(4): 913-920.
29. Mehlen P, Fearon FR. Role of the dependence receptor DCC in colorectal cancer pathogenesis. J Clin Oncol, 2004, 22(16): 3420- 3428.
30. Bonneton C,Lavue L,Thiery JP.Current data on the role of APC protein in the origin of colorectal cancer.Bull Cancer,1997,84:1053-1060.
31.Kamoshida S, Matsuoka H, Shiogama K, et al. Immunohistochemical analysis of thymidylate synthase, p16, cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Int, 2004, 54(8): 564-575.
32. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancer genesis. Hum Mol Genet, 2000, 9(2): 283-287.
33. Miyaki M, Kuroki T. Role of Smad (DPC4) inactivation in human cancer. Biochem Biophys Res Commun, 2003, 306(4): 799-804.
34. Kapitanovic S, Cacev T, Berkovic M, et al. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. J Clin Pathol, 2004, 57(12): 1312-1318.
35. Kirsch DG,Kastan MB:Tumor suppressor p53:implication for tumor development and prognosis.J Clin Oncol,1998;16:3158-68.
36.Giaretti W,Rapallo A,Sciutto A,et al.intratumor heterogeneity of K-rasand p53 mutations among human colorectal adenomas containing early cancer.Anal Cell Pathobl,2000,21:49-57.
37.Hermeking H,Eick D.Mediation of c-myc-induced apoptosis by p53.Science,1994,265:2091-2093.
38. ArendsJW.Molecular interactions in the Vogelstein model of colorectal carcinoma[J].JPathol,2000,190(4):412-416.
39. Hatch SB, Lightfoot HM, Garwacki CP, et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res, 2005, 11(6): 2180-2187.
40.Peltomaki P.Deficient DNA mismatch repair:a common etiologic factor for colon cancer.Hum Mol Genet,2001,10:735-740.
41.Marcus VA,Madlensky L,Gryfe R,et al.Immonohisto chemistry for hMLH1 and hMLH2:a practical test for DNA mismatch repair deficient tumors.Am J Surg Pathol,1999,23:1248-1255.
42.M.Colombino A,Cossu MF,Dedola,et al.Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma[J].Annals of oncology,2002,13:1447-1453.
43.Riad Haddad,Robert T,Ogilvive,et al.Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases[J].Annal of surgical oncology,2004,11:977-982.
44. Ahlquist DA,Skoletsky JE,Boynton KA,et al. Colorectal cancer screening by detection of altered human DNA in stool:feasibility of a multistage assay panel. [J] Gastroenterology,2000,119(5):1219-1227.
45. Qiu H,Sirivongs P,Rothenberger M,et al. Molecular prognostic factorsin rectal cancer treated by radiation and surgery. [J] Dis Colon Rectum,2000,43(4):451-459.
46. Edler D,Hallstrom M,Johnston PG,et al. Thymidylate synthase expression:an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. [J] Clin Cancer Res,2000,6(4):1378-1384.
47. Elsaleh H,Joseph D,Grien F,et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. [J] Lancet,2000,355(9217):1745-1750.
48. Nakayama Y,Nagashima N,Minagawa N,et al.Relationships between tumor associated macrophages and clinic pathological factors in patients with colorectal cancer[J].Anticancer Res,2002,22(6C):4291- 4296.
49. OnoM,TorisuH,FukushiJ,etal.Biological implications of mac rophage infiltration in human tumor angiogenesis[J].Cancer Che mother Pharmacol,1999,43(5):69-71.
50. CsiszarA,SzentesT,HarasztiB,etal.The pattern of cytokine gene expression in human colorectal carcinoma[J].PatholOncol Res,2004, 10(2): 109- 116.
51. Konishi N,Miki C,Yoshida T,et al.Interleukin 1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma [J] . Oncology , 2005,68 (2-3):138-145.
52.Maihofner C,Charalambous MP,Bhambra U,et al.Expression of cyclooxygenase2 parallels expression of interleukin-1 beta,interleukin- 6 and NF-kappa B in human colorectal cancer[J].Carcinogen esis,2003,24(4): 665-671.
53.MikiC,KonishiN,OjimaE,etal.C-reactive protein as aprognostic vari able that reflects uncontrolled upregulation of the IL-1 IL-6net work system in colorectal carcinoma[J].DigDisSci,2004,49(6):970-976.
54.Lee YJ,Song JJ,Kim JH,et al.Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediatedca spase signal transduction pathway[J].ExpCellRes,2004,293(1):129-143.
55.Thomas KA.Vascular endothelial factor,a potent and selective angiogenic agent [J].J Biol Chem,1996,271(2):603-606.
56.Brown LF,Berse B,Jackman RW,et al.Expression of vascular permeability factor(vascular endothelial growth factor)and its receptors in breast cancer[J].Hum Pathol,1995,26(1):86-91.
57.Takahashi Y,Kitadai Y,Corazon D,et al.Expression of vascular endothelial growghe factor and its receptor,KDR,correlated with vasculary,metastasis and proliferation of human colon cancer[J].Cancer Res,1995,55(18):3964-3968.
58.Yamamoto S,Konishi I,Mondai M,et al.Expression of vascular endothelial growth factor(VEGF)in epithelial ovarian neoplasm: correlation with clinlcopathology and patient survival,and analysis of serum VEGF levels[J].Br J Cancer,1997,76(9):1221-1227.
59.Senger DR,Vande Walter L,Brown LF,et al.Vascular permeability factor(VPE,VEGF)in tumor biology[J].Cancer Metastasis Rev,1993,12(3-4):303-324.
60.Dirix LY,Vermeulen PB,Pawinski A,et al.Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascularendothelial growth factor in sera of cancer patients[J].Br J Cancer,1997,76(2):238-243.
61.冯海洋,李德川,徐笑红.胃癌患者血清 VEGF 水平的临床研究[J].实用癌症杂志,2002,17(2):203-204.
62. BeRNArdPS,WittwerCT.Real-time PCR technology for cancer diag nostics[J].Clin Chem,2002,48(8):1178-1185.
63. CAROEKAB HOLMSTROM,LOUHIMOJ,STENMANUH,et al.CEA, CA199, and CA724 improve the diagnostic accuracy in gastrointestinal cancers[J].Antic cancer Res,2002,22:2311.
64. 张海平,王美芝,崔复宪等,血清 CEA、CA199 及 CA242 在消化系统肿瘤组织中的表达,齐鲁医学杂志,2006,21(5)413-422。
65. Seifert JK,Junginger T.Prognostic factors for cryotherapy of colorectal liver metastases.Eur J Surg Oncol,2004,30:34-40.
66. JiangJT,WuCP,DengHF,etal.Serum levels of TSGF,CA242 and CA199 in pancreatic cancer.World JouRNAl of Gastroenterology. 2004, 10(11): 1675-77.
67. TuomolaM,VainioJ,LovgrenT.Rapid time-resolved immunoflu orometric assay for the measurement of creatine kinase in serum and whole blood samples.Agric Food Chem.2002,50(23):6659-62.
68.高岩,陈志周,范振符,等.CA199 免疫放射分析在肿瘤诊断中的应用[J].标记免疫分析与临床,1997,4(2):87-89.
69.Kim CW,Kin JI,Park SH,et al.Usefulness of plasma tumor M2 pyruvate kinase in the diagnosis of gastrointestinal cancer.Korean J Gastroenterol, 2003,42 (5):387-393.
70.Hardt PD,Toepler M,Ngoumou B,et al.Fecal pyruvate kinaseconcentrations(ELISA based on a combination of colne 1 and clone 3 antibodies)for gastric cancer screening.Anti cancer Res,2003,23(2A): 855-857.
71.Schneider J,Schulze G.Comparison of tumor M2 pyruvate kinase(tumor M2 PK),carcino embryonic antigen(CEA),carbohydrate antigens CA199 and CA724 in the diagnosis of gastrointestinal cancer.Anti cancer Res,2003,23(6D):5089-5093.
72. Albrethsen J,Bogebo R,Gammeltoft S,et al.Upregulated expression of human nertrophil peptides1,2 and 3(HNP1 3)in colon cancer serum and tumours:a biomarker study[J].BMC Cancer,2005,19(5):8.
73.Turck N,Richert S,Gendry P,et al.Proteomic analysis of nuclear proteins from proliferative and differentiated human colonic intestinal epithelial cells[J].Pro teomics,2004,4(1):93-105.
74. 陈虞梅.肿瘤标记物在结直肠癌中的临床应用和研究[J].国外医学放射医学核医学分册,2005,29(3):101-104.
75. 董新舒.直肠癌根治手术应遵循的四原则[J].中国实用外科杂志,2005,25(4):212-214.
76. 郁宝铭.低位直肠癌外科治疗的新理念和发展趋势[J].中国实用外科杂志,2005,25(3):129-130.
77. Heald RJ,Husband EM,Ryall RDH.The mesorectum in rectal cancer surgery:the clue to pelvic recurrence[J]?Br J Surg,1982,69:613～616.
78. 郁 宝 铭 . 低 位 直 肠 癌 的 诊 治 进 展 [ J ]. 中 国 实 用 外 科 杂志,2002,22(1):34-37.
79.Enker WE,Havenga K,Polyak T,et al.Abdomino perineal resection via cancer[J].World J surg,1997,21(7):715-20.
80.Cao LP,Ding GP,Que RS,et al.Influence of CO2 pneumoperitoneumon intracellular PH and signal transduction in cancer cells[J].J Zhe jiang Univ Sci B,2005,6(7):650-655.
81.Ishida H,Nakada H,Takeuchi I,et al.Distribution of intrasplenically injected colon cancer cells following pneumoperitoneum in mice[J].Surg Endosc,2003,17(8):1278-1282.
82.Patankar SK,Larach SW,Ferrara A,et al.Prospective comparison of laparoscopic vs open resections for colorectal adenocarcinoma over a ten-year period[J].Dis Colon Rectum,2003,46(5):601-611.
83.Mehta PP,Griffin J,Ganta S,et al.Laparoscopic-assisted colon resections long-term results and survival[J].JSLS,2005,9(2):184-188.
84. Salts LB,Cox JV,Blanke C,et al.Irinotecan stydy Group:irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer[J].N Engl J Med,2000,343(13):905-14.
85.DeGramont A,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16):29-38.
86. 张 小 田 . 进 展 期 结 直 肠 癌 的 内 科 治 疗 进 展 [ J ]. 癌 症 进展,2007,5(1):35-40.
87.李苏宜.刘玉林,顾小怡,等.草酸铂联合氟尿嘧啶、醛氢叶酸治疗晚期结直肠癌的临床观察[J].临床肿瘤学杂志,2006,11(8):612-614.
88.高峻,刘晓玲.紫杉醇联合顺铂、亚叶酸钙、5-氟尿嘧啶治疗晚期胃癌
39 例临床观察[J].肿瘤研究与临床,2007,19(1):41-43.
89. Robert D,Madoff MD.Chemoradio therapy for rectal cancer when,why and how?[J].N Engl J Med,2004,351(17):1790-1792.
90.Sauer R,Becer H,Hohenberger W,et al.Preoperative versuspost operative chemoradio therapy for rectal cancer[J].N Engl J Med,2004,351(7): 1731-1740.
91.Colorectal Cancer Collaboration Group.Adjuvant radio therapy for rectal cancer:a systematic over view of 8507 patients from 22 randemised trials[J].Lancet,2001,358(9290):1291-1304.
92.Tjandra JJ,Kilkenny JW,Buie WD,et al.Practice parameters for the management of rectal cancer(revised)[J].Dis Colon Rectum,2005,48(3): 411-423.
93.顾晋.直肠癌手术治疗的热点问题.中国实用外科杂志.2007,27(6):431-433.
94.Lindauer M, Rudy W, Gudcel B,et al. Gene transfer of costimulatorry of molecules into a human colorectal cancer cell line:requirement of CD50,CD80,and Class II MHC expression for enhanced immunogenicity [J] . Immunology ,1998 ,93 (3):390-7.
95. Bennett JJ,Malhotra S,Wong RJ,et al.Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer[J].Ann Surg,2001,233(6):819-26.
96.Eguchi J,Hiroishi K,Ishii S,et al.Interferon-alpha and interleukin-12 gene therapy of cancer[J].Cancer Immunol Imunnother , 2003,52(6):378-86.
97.Hu JY,Li GC,Wang WM,et al.Transfection of colorectal cancer cells with chemokine MCP-3(monocyte chemotactic protein-3 )gene retards tumor growth and inhibits tumor metastasis[J].World J Gastroenterol,2002,8(6):1067-72.
98.Nyati MK,Symon Z,Kievit E,et al.The potential of 5-fluorocyosine/cytosine deaminase enzyme prodrug in an intrahepatic colon cancer model[J]. Gene Ther,2002,9(13):844-9.
99.Pierrefite Carle V,Baque P,Gavelli A,et al.Subcutaneous or intrahepatic injection of suicide gene modified tumor cells induces a systemic antitumor sesponse in a metastatic model of colon carcinoma in rats[J].Gut,2002,50(3):387-91.
100. Lee YJ,Galoforo SS,Battele P,et al.Replicating adenoverial vectormediated of a heat-inducible suicide gene for gene therapy[J]. Cancer Gene Ther,2001,8(6):397-404.
101.Shen LZ,Wu WX,Xu DH,et al.Specific CEA-producing colorectal carcinoma cell killing with recombinant adnoviral vector containing cytosine deaminase gene[J].World J Gastroentorol,2002,8(2):270-5.
102. Kwong KY,Zou Y,Dan CP,et al.The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway[J]. Oncogene, 2002,21(54):8340-6.
103.Mearadji A,Breeman W,Hofland L,et al.Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide:a new treatment for liver metastases[J].Aun Surg,2002,236(6):722-9.
104.Adachi Y,Lee CT,Coffee K,et al.Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines[J].Gastroenterology,2002,123(4):1191-204.
105. Asanuma K, Tsuji N, Endoh T, et al. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol, 2004, 172(6): 3922- 3929.
106.Shi W,Teschendorf C,Muzyczka N,et al.Adeno-associated virus- mediated gene transfer of endosstatin inhibits angiogensis and tumor growth in vivo[J].Cancer Gene Ther,2002,9(6):513~21
107.Shi W,Teschendorf C,Muzyczka N,et al.Gene therapy of endostain enhances the treatment efficacy of radiation[J].Rdiother Oncol,2003, 66(1):1~9.
108.Yano J, Hirabayashi K, Nakagawa S, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.Clin Cancer Res, 2004, 10(22): 7721-7726.
109.Smakman N, Kranenburg O, Vogten JM, et al. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Clin Cancer Res, 2005, 11(1): 41-48.
110. Koppe MJ,Oyen WJ,Bleichrodt RP,et al.Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioim munotherapy in nude mice with small peritoneal metastases of colonic origin[J].Cancer Immunol Immunother,2006,55(1):47-55.
111.Scheele J,Stangl R,Altendorf Hofmann A,et al.Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery, 1991, 110: 13-29.
112.Finan PJ,Marshall RJ,Cooper EH,et al.Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer:A clinical and computer analysis.Br J Surg,1985, 72:373-7.
113.Fong Y,Fortner J,Sun RL,et al.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:Analysis of1001 consecutive cases.Ann Surg,1999,230:309-18.
114.Tomoyuki K,Kenzo Y,Takashi H,et al.The rapeutic results for hepatic metastasis of colorectal cancer with special reference to effect iveness of hepatectomy.Dis Colon Rectum Suppl,2003,46(10):S22.
115.Fong Y.Hepativ colorectal metastasis:Current surgical therapy,selection criteria for hepatectomy,and role for adjuvant therapy.Advances in Surgery,2000,34:351-81.
116. Hohenberger P,Schlag P,Schwarz V,et al.Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer.J Surg Oncol,1990,44:245-51.
117.Folprecht G,Kohne CH.The role of new agents in the treatment of colorectal cancer.On cology,2004,66(1):1-17.
118.Bismuth H,Adam R,Levi F,et al.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg, 1996,224:509-22.
119. Huang A,McCall JM,Weston MD,et al.Phase I study of percutaneouscry therapy for colorectal liver metastasis.Br J Surg,2002, 89:303-10.
120. Reenan RA.Molecular determinants and guided evolution of species-specific RNA editing.Nature,2005,434:409-413.
121. Keller W,Wolf J,Gerber A.Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion.FEBS Lett,1999, 452(1~2): 71-76.
122. Maas S,Rich A.Changing genetic information through RNA editing.Bioessays,2000,22:790-802.
123. Valente L,Nishikura K.ADAR gene family and A-to-I RNA editing:diverse roles in postrans criptional gene regulation.Prog Nucleic Acid Res Mol Biol,2005,79:299-338.
124. Barlati S,Barbon A.RNA editing:a molecular mechanism for the fine modulation of neuronal transmission.Acta Neurochir,2005,93:53-57.
125.Hoopengardner B,Bhalla T,Staber C.Nervous system targets of RNA editing identified by compareative genomica. Science, 2003, 301: 832-836.
126.Tonkin LA,Saccomanno L,Morse DP,et al.RNA editing by ADARs is important for normal behavior in Caenorhabditis elegans.EMBO J,2002,21:6025-6035.
127. Sommer B,Kohler M,Sprengel R,et al.RNA editing in brain control sadeterminant of inoflowing lutamate gatedchannels [J]. Cell,1991,67 (1):11-19.
128. Haub M,Keller W.RNA editing by adenosinedea minases gene rates RNA and protein diversity[J].Biochimie,2002,84(8):791-803.
129.George CX,Wagner MV,Samuel CE.Expression of interfereon- inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involvesissue- selective promoter utilizeation and alteRNAtive splicing.J Biol Chem,2005, 280(15):15020-15028.
130. 张德新,赵澎涛,赵青川,等。小鼠肝脏RNA编辑酶 ADAR14种剪切体:克隆、表达及功能分析,生物化学与生物物理进展,2006,33(7):635-640.
131. Yang JH,Sklar P,Axel R,et al.Editing of glutamate receptor subunit Bpre mRNA in vitro by site specific deamination of adenosine[J]. Nature,1995,374(6517):77-81.
132. 罗晓星,杨静华.全组织提取物检测 A-to-IRNA 编辑酶活性[J].生物技术,2002,12(3):8-9.
133.Athanasiadis A,Rich A,Maas S.Widespread A-to-I RNAeditin g of Alu-containing mRNAsin the human transcriptome[J].PLo S Biol,2004, 2(12): 2144-58.
134. 罗晓星,杨静华.内毒素对小鼠多种组织中 A至 IRNA 编辑酶活性和mRNA 中肌苷的诱导[J].科学通报,2002,10(20):1556～1560.
135. Keegan LP,Gallo A,O’Connell MA.Development,Survival is impossible without an editor[J].Science,2000,290(5497):1707-9.
136. Yang W,Cendrimada TP,Wang Q,et al.Modulation of micro RNA processing and expression through RNA editing by ADAR deaminases.Nat Struct Mol Biol,2006,13(1):13-21.
137.Rueter SM,Dawson TR,Emeson RB.Regulation of alteRNAtive splicing by RNA editing.Nature,1999,399(6731):75-80.
138. Yang JH,Luo X,Nie Y,et al.Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response tonflammation . Immunology, 2003,109(1):15-23.
139. Liu Y,George CX,Patteron JB,et al.Functionally distinct double- stranded RNA-binding domains associated with alteRNAtivesplics site variants of the interferon-inducible double- stranded RNA specific adenosine deaminase.J Biol Chem,1997, 272(7): 4419-28.
140. Taylor DR,Puig M,Darnell ME,et al.New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity throughADAR1.J Virol,2005,79(10):6291-6298.
141.Hartwig D,Schutte C,Warnecke J,et al.The large form of ADAR1 is responsible for enhanced hepatitis delta virus RNA editing in interferon alpha stimulated host cells.J Viral Hepat,2006, 13(3):150- 157.
142.Yang W,Wang Q,Howell KL,et al.ADAR1 RNA deaminase limits short interfering RNA efficacy in mammalian cells.J Biol Chem,2005, 280(5):3946-3953.
143.Zheng ZM,Tang S,Tao M.Development of Resistance to RNA I in Mammalian Cells.Ann NY Acad Sci,2005,1058:105-118.
144. Wang Q,Khilan J,Gradue P,et al.Requirement of the RNA editing deaminase ADAR1 gene for embry on ice rythropoiesis [J]. Science,2000,290(5497):1765-1768.
145. Patterson JB,Thomas DC,Hans SL,et al.Mechanism of interfere on action:double stranded RNA specific adenosine deaminase from human cells is inducible by alpha and gamma interferons [J]. Virology,1995,210(2):508-511.
146. 孔亚林,张洪涛,赵青川,等.共培养体系中小鼠淋巴细胞 RNA 编辑酶的表达[J].第四军医大学学报,2006;27(5)∶392-395.
147. Zhao QC,Zhang DX,Luo XX,et al.Changs of RNA editase ADAR1 during mouse primary lymphocy teprolife ration[J].Chin J Cell Mol Immunol,2002,18(3):208-210.
148. Rabinovici R,Kabir K,Chen M,et al.ADAR1 is involved in the development of microvascular lung injury[J].Circ Res, 2001,88(10) 1066-1071.
149.Zhenji Gan,Zhao L,Yang L,et al:RNA Editing by ADAR2 Is Metabolically Regulated in Pancreatic Islets and –Cells .J. Biol. Chem., 2006,281(44): 33386-94.
150.Sprengel R,Higuchi M,Monyer H,et al.Glutamate receptor channels:apossible link between RNA editing in the brain and epilepsy[J].Adv Neurol,1999,79(2):525-534.
151.Vanden Leeuwen FW,de Kleijn DP,vanden Hurk HH,Frame shift mutants of beta amyloid precurs or protein and ubiquitin B in A1z heimer’s and Down patients[J].Science,1998,279(5348):242-247.
152. Kortenbruck G,Berger E,Speckmann EJ,et al.RNA editing at the Q/R site for the glutamate recaptor subunits GLUR2,GLUR5,and GLUR6 in hippocampus and temporal cortex from epileptic patients[J]. Neurobiol Dis,2001;8(3):459.
153. Maas S,Patt S,Schrey M,et al.Underediting of glutamate recaptor GluR-B mRNA in malignant gliomas.Proc Natl Acad Sci,2001,98:14687-14692.
154. Levanon EY,Eisenberg E,Yelin R,et al.Systematic identifyication of abundant A-to-I editing sites in the human transcriptome.Nature Bio, 2004, 22: 1001-1005.
155. Mukhopadhyay D,Anant S,Lee RM,et al.C-->U editing of neuro fibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1,the catalytic subunit of the apoli poprotein BmRNA-editing enzyme[J].Am J Hum Genet,2002,70(1):38～50.
156. Youngren KK,Coveney D,Peng X,et al.The Termutation in the deadend genecausesgerm cell loss and testiculargerm cell tumours[J]. Nature,2005, 435(7040): 360～364.
157. 张洪涛,窦科峰.ADAR1mRAN 在肝癌及癌旁组织的表达及意义 现代肿瘤学.2006,14(5): 577-579.
158. Maas S,Rich A,Nishikura K.A-to-I RNAediting:recent news and residual mysteries[J].J Biol Chem,2003,278(3):1391～1394.
159. Brunschwig EB, Wilson K, Mack D, et al. PMEPA1, a transforming growth factor-beta-induced marker of termina colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res, 2003, 63(7): 1568-1575.
160.Chintharlapalli S, Smith R, Samudio I, et al. 1, 1-Bis(3’)-1-(p- substitutedphenyl) methanes induce peroxisome proliferators- activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res, 2004, 64(17): 5994-6001.
161.Hudgins WR,Shack S,Myers CE,et al. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem pharmacol,1995,50(8):1273-1279.
162.Boudoulas S,Lush RM,McCall NA,et al. Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Ther Drug Monit, 1996, 18(6):714-720.
163.James MO, Smith RL, Williams RT, et al. The conjugation of phenylacetic acid in man, sub-human primates and some nonprimate species. Proc R Soc Lond B Biol Sci, 1972, 182(66): 25-35.
164. Brusilow SW, Danney M, Waber LJ, et al. Treatment of episodichyperammonemia in children with inborn errors of urea synthesis. N Engl J Med, 1984, 310(25): 1630-1634.
165.Simell O, Sipila L, Rajantie J, et al. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res, 1986, 20(11): 1117-1121.
166. Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol, 1986, 81(7): 540-543.
167.Maestri NE,Clissold DB,Brusilow SW,et al.J Pediatr, Long-term survival of patients with argininosuccinate synthetase deficiency. 1995,127(6):929-935.
168. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes Memorial Lecture. Cancer Res, 1983, 43(8): 3466-3492.
169.Medina MA. Glutamine and cancer. J Nutr, 2001, 131(9): 2539S- 2542S; discussion 2539S-2551S.
170. Samid D,Shack S,Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest,1993,91(5):2288-2295.
171.Samid D,Shack S,Sherman LT,et al. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res,1992,52(7):1988- 1992.
172. Neish WJ. Phenylacetic acid as a potential therapeutic agent for the treatment of human cancer. Experientia, 1971, 27(7): 860-861.
173. Pineau T,Hudgins WR,Liu L,et al. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetateand its analogs. Biochem Pharmacol,1996,52(4):659-667.
174. Zhang FL,Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem,1996,65:241-269.
175. Thibout D , Kraemer M , Di Benedetto M , et al. Sodium phenylacetate (PA) induces modifications of the proliferation ,the adhesionand the cell cycle of tumoral epithelial breast cells. Anticancer Res ,1999 , 19 (3A) : 2121-2126.
176. Di Benedetto M , Starzec A , Colombo BM ,et al. Aponecrotic , antiangiogenic and antiproliferative effects of a novel dextran derivativeon breast cancer growth in vitro and in vivo. Br J Pharmacology ,2002 , 135 (8) :1859-1871.
177. Ferrandina G, Melichar B , Loercher A , et al. Growth inhibitory effects of sodium phenylacetate (NSC3039) on ovarian carcinoma cellsin vitro. Cancer Res , 1997 , 57 (19) : 4309-4315.
178. Bossy Wetzel E , Newmeyer DD , Green DR. Mitochondrial cytochrome c release in apoptosis occurs upsteam of DEVD- specificcaspase activation and independently of mitochondrial transmembrane depolarization. EMBO J , 1998 , 17 (1) : 37-49.
179. Suzuki N , Urano J , Tammanoi F. Faenesyltransferase inhibitorsinduce cytochromec release and caspase-3 activation preferentiallyin transformed cells. Proc Natl Acad Sci USA , 1998 , 95 ( 26) : 15356-15361.
180. Marcelli M , Cunningham GR , Walkup M , et al. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP : overexpression of caspase-7 as a new gene therapy strategyfor prostatecancer. Cancer Res , 1999 , 59 (2) : 382-390.
181. Adam L , Crepin M , Israel L. Tumor growth inhibition , apoptosis ,and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylac-etate and tamoxifen combination. Cancer Res , 1997 , 57 (6) : 1023-1029.
182. Vasse M , Thibout D , Paysant J , et al. Decease of breast cancer invasiveness by sodium phenylacetate (PA) is associated with anincreased expression of adhesive molecules. Br J Cancer , 2001 , 84(6) : 802-807.
183. Adam L , Crepin M , Savin C , et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF-7ras cells in vitro and in nude mice. Cancer Res , 1995 , 55 ( 22) :5156-5160.
184. Di Benedetto M , Kourbali Y, Starzec A ,et al. Sodium phenylace enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice. Br J Cancer , 2001 , 85 (6) :917-923.
185. Samid D, Ram Z, Hudgins SS, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res, 1994, 54(4): 891-895.
186. Sidell N, Wada R, Han G, et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer, 1995, 60(4): 507-514.
187. Liu L,Shack S, Steler-Stevenson WG ,et al. Differentiation of cultured human melanoma cells induced by the aromatic fatty acidsphenylacetate and phenylbutyrate. J Invest Derama,1994, 103(3):335- 340.
188. Liu L,Hudgins WR,Miller AC,et al. Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine,1995, 7(5):449- 456.
189. Stockhammer G, Manley GT, Johnson R, et al. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg, 1995, 83(4): 672-681.
190. Adam L, Crepin M, Savin C, et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res, 1995, 55(22): 5156-5160.
191. Prasanna P, Thibault A, Liu L, et al. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem, 1996, 66(2): 710-716.
192. Pahan K, Sheikh FG, Namboodiri AM, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest, 1997, 100(11): 2671-2679.
193. Sidell N, Chang B, Yamashiro JM, et al. Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res, 1998, 239(1): 169-174.
194. Cosentini E, Haberl I, Pertschy P, et al. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. Int J Oncol, 2001, 19(5): 1069-1074.
195. Li XN, Parikh S, Shu Q, et al. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res, 2004, 10(3): 1150-1159.
196. Ram Z, Samid D, Walbridge S, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res, 1994, 54(11): 2923- 2927.
197. Ozawa T, Lu RM, Hu LJ, et al. Radiopotentiation of human brain tumor cells by sodium phenylacetate. Cancer Lett, 1999, 142(2): 139 -146.
198. Samid D, Wells M, Greene ME, et al. Peroxisome proliferators -activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res, 2000, 6(3): 933-941.
199. Sarraf P, Mueller E, Jones D,et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med. 1998, 4(9): 1046-1052.
200. Thibault A,Cooper MR,Figg WD,et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res,1994,54(7):1690-1694.
201. Thibault A, Samid D, Cooper MR, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer, 1995, 75(12):2932-2938.
202. del Rosario M, Werlin SL, Lauer SJ, et al. Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J Clin Gastroenterol, 1997, 25(4): 682-684.
203. Maestri NE,Brusilow SW,Clissold DB,et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med, 1996, 335(12): 855-859.
204. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol, 1999, 17(3): 984-990.
205. Di Benedetto M , Starzec A , Vassy R , et al. Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice byearly and late treatment with a novel dextran derivative. Br J Cancer , 2003 , 88 (12) :1987-1994.
206. Gervelas C , Avramoglou T , Crepin M , et al. Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA dextran conjugate. Anticancer Drugs , 2002 , 13 (1) : 37-45.
207. Sebbah Louriki M , Colombo BM , el Manouni D , et al. A new phenylacetate bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res , 2002 , 22(6C) : 3925-3931.
208. Piscitell SC,Thibault A,Fugg WD,et al. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J ChnPharmacol,195,35(4):368-373.
209. Newmark HL,Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem,1995:22(suppl):247-253.
210. Wexler EJ, Gravallese EM, Czerniak PM, et al. Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments. Clin Cancer Res, 2000, 6(8): 3361-3370.
211.田宇,赵兴利,陈宝琴,等.苯乙酸对胶质瘤细胞增殖周期的抑制作用.中国耳鼻咽喉颅底外科杂志.2000,6(2):65-67.
212. Bacon CL, O’Driscoll E, Regan CM, et al. Valproic acid suppresses G1 phase-dependent sialylation of a 65kDa glycoprotein in the C6 glioma cell cycle. Int J Dev Neurosci, 1997, 15(6): 777-784.
213. 牛富文 主编.医用分子生物学.第 1 版.河南:河南医科大学出版,1997.208-209.
214. Miller AC, Xu J, Stewart M, et al. Suppression of depleted uranium- induced neoplastic transformation of human cells by the phenyl fatty acid, pheylacetate: chemoprevention by targeting the p21RAS protein pathway. Radiat Res, 2001, 155(2): 163-170.
215. Onishi T, Yamakawa K, Franco OE, et al. p27Kip1 is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells. Anticancer Res, 2000, 20(5A): 3075-3081.
216. Wong SK, Sato S, Lazinski D W. Substrate recognition by ADAR1 and ADAR2 [J].RNA,2001,7(6):846-58.
217. Kim DD, Kim TT, Walsh T, Kobayashi Y, Matise TC, Buyske S,Gabriel A. Widespread RNA editing of embedded alu elements in the human transcriptome. Genome Res. 2004;14:1719–1725.
218. Vila MR, Gelpi C, Nicolas A, Morote J, Schwartz S Jr, Schwartz S, Meseguer A. Higher processing rates of Alu-containing sequences in kidney tumors and cell lines with overexpressed Alu-mRNAs. Oncol Rep. 2003;10(6):1903–1909.
219. Levanon EY, Eisenberg E. Algorithmic approaches for identification of RNA editing sites. Brief Funct Genomic Proteomic. 2006;5:43–45.
220. Blow M, Futreal PA, Wooster R, Stratton MR. A survey of RNA editing in human brain. Genome Res. 2004;14:2379–2387.
221.Monrudee Sukma ,Michihisa Tohda,Hiroshi Watanabe,Kinzo Matsumoto.The mRNA Expression Differences of RNA Editing Enzymes in Differentiated and Undifferentiated NG108-15 Cells.J Pharmacol Sci 2005;98(4),467-470.
222. Haifang Wang,Zheng Hou,Yumei Wu,Xue Ma ,Xiaoxing Luo.p150 ADAR1 isform involved in maintenance of HeLa cell proliferation.BMC Cancer.2006,6:282 doi:10.1186/1471-2407-6-282.
